Improving clinical trial outcomes in amyotrophic lateral sclerosis
Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same
historically intransigent problem that has existed since the initial description of the disease in …
historically intransigent problem that has existed since the initial description of the disease in …
[HTML][HTML] Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee
S Vucic, KHS Chen, MC Kiernan, M Hallett… - Clinical …, 2023 - Elsevier
The review provides a comprehensive update (previous report: Chen R, Cros D, Curra A, Di
Lazzaro V, Lefaucheur JP, Magistris MR, et al. The clinical diagnostic utility of transcranial …
Lazzaro V, Lefaucheur JP, Magistris MR, et al. The clinical diagnostic utility of transcranial …
Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …
Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial
BJ Wainger, EA Macklin, S Vucic, CE McIlduff… - JAMA …, 2021 - jamanetwork.com
Importance Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease
of the motor nervous system. Clinical studies have demonstrated cortical and spinal motor …
of the motor nervous system. Clinical studies have demonstrated cortical and spinal motor …
The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins
Microglial NLRP3 inflammasome activation is emerging as a key contributor to
neuroinflammation during neurodegeneration. Pathogenic protein aggregates such as β …
neuroinflammation during neurodegeneration. Pathogenic protein aggregates such as β …
Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques
MAJ van den Bos, N Geevasinga… - International journal of …, 2019 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative
disorder of the motor neurons, characterized by focal onset of muscle weakness and …
disorder of the motor neurons, characterized by focal onset of muscle weakness and …
Motor potentials evoked by transcranial magnetic stimulation: interpreting a simple measure of a complex system
Transcranial magnetic stimulation (TMS) is a non‐invasive technique that is increasingly
used to study the human brain. One of the principal outcome measures is the motor‐evoked …
used to study the human brain. One of the principal outcome measures is the motor‐evoked …
Risk factors and emerging therapies in amyotrophic lateral sclerosis
N Nowicka, J Juranek, JK Juranek… - International journal of …, 2019 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disease
characterized by a permanent degeneration of both upper and lower motor neurons. Many …
characterized by a permanent degeneration of both upper and lower motor neurons. Many …
Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS
K Weskamp, EM Tank, R Miguez… - The Journal of …, 2020 - Am Soc Clin Investig
Cortical hyperexcitability and mislocalization of the RNA-binding protein TDP43 are highly
conserved features in amyotrophic lateral sclerosis (ALS). Nevertheless, the relationship …
conserved features in amyotrophic lateral sclerosis (ALS). Nevertheless, the relationship …
Riluzole, disease stage and survival in ALS
T Dharmadasa, MC Kiernan - The Lancet Neurology, 2018 - thelancet.com
Comment 386 www. thelancet. com/neurology Vol 17 May 2018 might be an early transient
effect, with other molecular pathways becoming more involved later. Such a proposition …
effect, with other molecular pathways becoming more involved later. Such a proposition …